CRP and cancer: These results highlight the complexity and dynamics of circulating biomarkers of sleep disruption during oncological treatment in cancer patients and suggest that commonly studied biomarkers such as sub-pathologically elevated CRP (detected by a high sensitivity test) or pro-inflammatory cytokines are not predictive for evaluating sleep disruption in cancer patients undergoing treatment.